aureus peptidoglycan. Through this analysis, we identified the 16-kDa C-terminal region as the minimum portion of ORF56 required for bactericidal activity. This 16-kDa protein (Lys16) containing the CHAP domain was purified and found to be stable. Adding 100 μg/ml purified Lys16 to MRSA clinical isolates reduced cell numbers by 99.9%, demonstrating its antibacterial property (Figure 2).

Using antibodies against Lys 16, we were able to localize BAY 63-2521 nmr the protein on the phage tail structure. CHAP domains are present in a wide variety of proteins, including phage endolysins, bacterial autolysins, and various eukaryotic proteins. Most proteins that contain a CHAP domain function are peptidoglycan hydrolases and are associated with amidases [35, 40]. No other known domains were identified in ORF56. Like the tail-associated lysin Tal2009, ORF56 undergoes autoproteolysis upon hyperexpression in an E. coli host [41]. Phage-encoded lytic enzymes typically have a modular organization consisting of a catalytic domain that degrades

the peptidoglycan and a binding R406 domain that recognizes the cell wall of the target bacterium [42]. However, no cell wall-binding domain could be identified in ORF56. NCBI BLAST [27] and Pfam [28] databases were used to compare cell wall targeting/binding domains of various Staphylococcus spp and their phages to select a suitable domain that could be fused to Lys16. Our objective was to generate a chimeric protein with high specificity of target recognition and potent antistaphylococcal activity. To this end, we combined the muralytic LY294002 molecular weight activity of Lys16

with the known specific bacterial cell wall-binding SH3b domain from lysostaphin [23]. The chimeric protein P128 displayed higher activity than Lys16 and was found to be potent against S. aureus (Figure 4). P128 was effective on a panel of MRSA ever and methicillin-sensitive S. aureus clinical isolates representing more than 3,000 isolates (Figure 7). In addition, we demonstrated the in vivo efficacy of P128 in a rat S. aureus nasal colonization model (Figure 8). We chose this model because growing evidence points to nasal carriage as the source of S. aureus infections in various clinical and community settings [43–45]. Although topical mupirocin is effective in clearing nasal S. aureus and reducing the incidence of infection, mupirocin resistance is limiting its preventative and therapeutic use [46, 47]. In our study, we used USA300, which is a community-acquired mupirocin-resistant MRSA strain of high clinical significance [48]. To our knowledge, this is the first report of USA300 use in a nasal colonization model. P128 applied to rat nares in the form of an aqueous gel either decolonized the nares of USA300 completely or significantly reduced cell numbers. Thus, P128 is a novel chimeric protein with potent antistaphylococcal activity and warrants further development for therapeutic use.